. Author manuscript; available in PMC: 2015 May 1.

Published in final edited form as: Lancet Infect Dis. 2014 Feb 20;14(5):388–396. doi: 10.1016/S1473-3099(14)70020-9

Table 2.

HIV-1 infection hazard ratios (vaccine:placebo), adjusted for baseline HSV-2

Cohort	Est. (95% CI); P-value	Interaction P-value	Time-varying HR P-value
Overall	1.70 (1.13, 2.55); 0.01	-	0.11
Ad5 seropositive	1.70 (1.08, 2.66); 0.02	0.98	0.51
Ad5 seronegative	1.70 (0.66, 4.40); 0.27	0.98	0.01
Women	1.42 (0.85, 2.36); 0.18	0.19	0.65
Men	2.46 (1.22, 4.93); 0.01	0.19	0.08
Men circumcised at baseline or on study	3.58 (1.16, 11.01); 0.03	0.38	0.02
Men uncircumcised throughout study	1.83 (0.74, 4.54); 0.19	0.38	0.29
Age ≤ 25 years	1.72 (1.04, 2.84); 0.03	0.96	0.41
Age > 25 years	1.66 (0.83, 3.32); 0.15	0.96	0.09
Soweto	2.40 (1.19, 4.86); 0.02	0.51	0.15
Cape Town	1.86 (0.84, 4.14); 0.13		0.51
KOSH	0.87 (0.33, 2.25); 0.77		0.93
eThekwini	1.91 (0.62, 5.94); 0.26		0.44
Medunsa	1.05 (0.21, 5.24); 0.95		0.50